The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable buzz within the sector. A shift away from Schedule I status, often viewed as outdated and hindering progress, could unlock significant opportunities for businesses. Reduced regulatory restrictions, alongside greater access to banking and fundin